The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
ApexOnco Front Page
Recent articles
GEN1286 looks dead, though MCLA-129 continues for now.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
Three private biotechs enter clinical trials, one targeting KRAS.
